Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
What's Your Reaction?
